Jiuzhitang Maker (beijing) Cell Technology Co.,ltd.

This early-stage trial will test the safety of a single intravenous dose of stem cells derived from human bone marrow in 42 people aged 6 and older with autism spectrum disorder. Participants will receive one of three different doses. The study will monitor for side effects and a…